| Author | Badaro, Roberto | |
| Author | Barbosa, Josiane Dantas Viana | |
| Author | Araújo Neto, Cesar Augusto de | |
| Author | Machado, Bruna Aparecida Souza | |
| Author | Soares, Milena Botelho Pereira | |
| Author | Senna, Valter de | |
| Author | Taddeo, Marcelo | |
| Author | Araújo, Lila Teixeira de | |
| Author | Durkee, Shane | |
| Author | Donninger, Raymond | |
| Author | Judge, Kevin | |
| Author | Saiyed, Zainulabedin | |
| Access date | 2024-04-18T18:16:49Z | |
| Available date | 2024-04-18T18:16:49Z | |
| Document date | 2023 | |
| Citation | BADARO, Roberto et al. A randomized clinical trial to evaluate the efficacy of L-carnitine L-tartrate to modulate the effects of SARS-CoV-2 infection. Frontiers in Nutrition, v. 10, p. 1-9, 2023. | en_US |
| ISSN | 2296-861X | en_US |
| URI | https://www.arca.fiocruz.br/handle/icict/63579 | |
| Sponsorship | Lonza Greenwood LLC., Greenwood, SC, Estados Unidos.
Centro de Pesquisa e Inovação da Universidade Senai-Cimatec de Salvador, Bahia, Brasil. | en_US |
| Language | eng | en_US |
| Publisher | Frontiers Media | en_US |
| Rights | open access | en_US |
| Subject in Portuguese | L-carnitina | en_US |
| Subject in Portuguese | COVID 19 | en_US |
| Subject in Portuguese | SARS-CoV-2 | en_US |
| Subject in Portuguese | Pneumonia | en_US |
| Subject in Portuguese | Infecção | en_US |
| Title | A randomized clinical trial to evaluate the efficacy of L-carnitine L-tartrate to modulate the effects of SARS-CoV-2 infection | en_US |
| Type | Article | en_US |
| DOI | 10.3389/fnut.2023.1134162 | |
| Abstract | Introduction: L-carnitine (LC) has been associated with inflammatory mediator reduction and with downregulating the angiotensin-converting enzyme-2 (ACE2) receptor, which is the target of SARS-CoV-2 attachment. Methods: This pilot phase 2 randomized, double-blind placebo-controlled trial contained two cohorts. Cohort 1 comprised 101 individuals with negative RT-PCR SARS-CoV-2 test results who cohabitated with an individual diagnosed with SARS-CoV-2 infection. Cohort 2 comprised 122 individuals with positive SARS-CoV-2 RT-PCR test results who were asymptomatic or had mild COVID-19 pneumonia symptoms. Participants in each cohort were randomized 1:1 to receive either 2 g elemental oral LC supplementation or placebo daily for 21 days. Primary endpoints included adverse events, SARS-CoV-2 infection incidence in Cohort 1, and disease progressions in Cohort 2. Secondary endpoints included between-group laboratory profile comparisons and Cohort 2 ACE1/ACE2 plasma levels. Disease progression was compared between the Cohort 2 groups using chest computed tomography. Results: In Cohort 1, two SARS-CoV-2 infections occurred in each group. The common adverse events included headache, dyspnea, and tiredness. In Cohort 2, platelet counts were elevated, and fibrinogen levels reduced in the LC group compared with those of the placebo group. Conclusion: Our study showed that LC was well-tolerated and suggests it modulates coagulation pathways. Furthermore, chest computed tomography images of the Cohort 2 LC group showed significant lung lesion improvement, suggesting that LC may slow COVID-19 progression. | en_US |
| Affilliation | Centro Universitário SENAI/CIMATEC. Instituto de Tecnologias em Saúde (ITS). Salvador, BA, Brasil. | en_US |
| Affilliation | Centro Universitário SENAI/CIMATEC. Instituto de Tecnologias em Saúde (ITS). Salvador, BA, Brasil. | en_US |
| Affilliation | Centro Universitário SENAI/CIMATEC. Instituto de Tecnologias em Saúde (ITS). Salvador, BA, Brasil / Diagnóstico por imagem. Salvador, BA, Brasil. | en_US |
| Affilliation | Centro Universitário SENAI/CIMATEC. Instituto de Tecnologias em Saúde (ITS). Salvador, BA, Brasil. | en_US |
| Affilliation | Centro Universitário SENAI/CIMATEC. Instituto de Tecnologias em Saúde (ITS). Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil. | en_US |
| Affilliation | Centro Universitário SENAI/CIMATEC. Instituto de Tecnologias em Saúde (ITS). Salvador, BA, Brasil. | en_US |
| Affilliation | Centro Universitário SENAI/CIMATEC. Instituto de Tecnologias em Saúde (ITS). Salvador, BA, Brasil / Universidade Federal da Bahia. Salvador, BA, Brasil. | en_US |
| Affilliation | Centro Universitário SENAI/CIMATEC. Instituto de Tecnologias em Saúde (ITS). Salvador, BA, Brasil. | en_US |
| Affilliation | Research and Development. Lonza Greenwood. Greenwood, SC, United States. | en_US |
| Affilliation | Research and Development. Lonza Biologics. Slough, United Kingdom. | en_US |
| Affilliation | Research and Development. Lonza Greenwood. Greenwood, SC, United States. | en_US |
| Affilliation | Research and Development. Lonza Greenwood. Greenwood, SC, United States. | en_US |
| Subject | L-carnitine | en_US |
| Subject | COVID-19 | en_US |
| Subject | SARS-CoV-2 | en_US |
| Subject | Pneumonia | en_US |
| Subject | Infection | en_US |
| DeCS | Carnitina | en_US |
| DeCS | COVID-19 | en_US |
| DeCS | SARS-CoV-2 | en_US |
| DeCS | Pneumonia | en_US |
| DeCS | Infecções | en_US |
